Moderna, Inc.
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 31, 2026 | Before market open | $145.00M | $-1.97 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 1, 2026 | Before market open | $389.00M | $-3.40 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 13, 2026 | Before market open | $678.00M | $-2.11 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $1.00B | $-0.51 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 1, 2025 | Before market open | $142.00M | $-2.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $108.00M | $-2.52 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 14, 2025 | Before market open | $1.00B | $-2.91 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $1.90B | $0.03 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 31, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | 2026 | $200.00M to $300.00M | Maintained |
| Research and development expenses | 2026 | $2.90B | Raised |
| Cost of sales | 2026 | $1.70B | Lowered |
| Year-end cash and investments | 2026 | $4.70B to $5.20B | Raised |
| Selling, general and administrative expenses | 2026 | $1.00B | Lowered |
| revenue growth | 2026 | 10% growth | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Moderna filed with the SEC
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Appoints Michael McDonnell to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
2025: A Year of Commercial Progress, Pipeline Momentum and Financial Discipline
Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Regulation FD disclosure · EX-99 to Form 8-K
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99 to Form 8-K
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Abbas Hussain Joins Moderna’s Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna R&D Day Highlights Progress and Strategic Priorities
Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
David Rubenstein Joins Moderna’s Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Provides Business and Pipeline Updates at 42 nd Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Creates New Executive Committee Role Ahead of New Product Launches
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
JAMES MOCK JOINS MODERNA AS CHIEF FINANCIAL OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stock Option Exercise and Charitable Giving
Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Jorge Gomez Joins Moderna as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K